Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
Abstract Background The blocking of the programmed cell death protein (PD-1)/programmed death-ligand 1 (PD-L1) axis has been found to have an anticancer activity against various types of cancer by enhancing T cell immunity, while there are no studies linking the PD-1/PD-L1 axis to chemotherapy drugs...
Main Authors: | Xiaoqiang Liu, Shaoya He, Huaming Wu, Hui Xie, Tao Zhang, Zhongliang Deng |
---|---|
Format: | Article |
Language: | English |
Published: |
Komiyama Printing Co. Ltd
2019-12-01
|
Series: | Environmental Health and Preventive Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12199-019-0835-3 |
Similar Items
-
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
by: Kazushige Yoshida, et al.
Published: (2020-01-01) -
Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01) -
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
by: Bingxin Zheng, et al.
Published: (2018-02-01) -
The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01) -
The clinical association of programmed death-1/PD-L1 axis, myeloid derived suppressor cells subsets and regulatory T cells in peripheral blood of stable COPD patients
by: Mingqiang Zhang, et al.
Published: (2024-03-01)